Sapanisertib

Generic Name: Sapanisertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₅N_₇O

CAS Number: 1224844-38-5

Unique Ingredient Identifier: JGH0DF1U03

Background: Sapanisertib has been used in trials studying the treatment of HCC, Solid Tumor, Gliosarcoma, Liver Cancer, and Glioblastoma, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

Phase 2

Active, not recruiting

Conditions: Advanced Lymphoma
Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Malignant Solid Neoplasm
Refractory Multiple Myeloma

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Sapanisertib

First Posted Date: 2024-04-30

Last Posted Date: 2024-11-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 49

Registration Number: NCT06390865

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Refractory Lymphoma
Refractory Multiple Myeloma
Advanced Lymphoma
Refractory Malignant Solid Neoplasm

Interventions: Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Drug: Sapanisertib

First Posted Date: 2024-04-26

Last Posted Date: 2024-11-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 35

Registration Number: NCT06385496

Locations: 🇺🇸
ECOG-ACRIN Cancer Research Group, Philadelphia, Pennsylvania, United States

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage IVA Lung Cancer AJCC v8
Metastatic Malignant Neoplasm in the Brain
Stage IV Lung Cancer AJCC v8
Leptomeningeal Neoplasm
Stage IVB Lung Cancer AJCC v8
Recurrent Lung Non-Small Cell Carcinoma

Interventions: Drug: Sapanisertib
Drug: Telaglenastat Hydrochloride

First Posted Date: 2020-01-31

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 85

Registration Number: NCT04250545

Locations: 🇺🇸
City of Hope at Irvine Lennar, Irvine, California, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸
Keck Medicine of USC Koreatown, Los Angeles, California, United States

and more 4 locations

Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations

Phase 2

Active, not recruiting

Conditions: Locally Advanced Bladder Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Bladder Carcinoma
Stage III Bladder Urothelial Carcinoma AJCC v6 and v7
Metastatic Transitional Cell Carcinoma
Stage IV Bladder Urothelial Carcinoma AJCC v7

Interventions: Drug: Sapanisertib

First Posted Date: 2017-02-08

Last Posted Date: 2024-11-13

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT03047213

Locations: 🇺🇸
Keck Medical Center of USC Pasadena, Pasadena, California, United States
🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Los Angeles General Medical Center, Los Angeles, California, United States

and more 17 locations

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Pancreatic Neuroendocrine Tumor G1
Pancreatic Neuroendocrine Tumor G2
Refractory Pancreatic Neuroendocrine Carcinoma

Interventions: Drug: Sapanisertib

First Posted Date: 2016-09-09

Last Posted Date: 2023-10-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 13

Registration Number: NCT02893930

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Bhadresh Nayak MD PC-Sterling Heights, Sterling Heights, Michigan, United States
🇺🇸
Central Care Cancer Center - Bolivar, Bolivar, Missouri, United States

and more 400 locations

Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma

Phase 1

Terminated

Conditions: High Grade Sarcoma
Recurrent Malignant Peripheral Nerve Sheath Tumor
Metastatic Undifferentiated Pleomorphic Sarcoma
Stage III Uterine Corpus Leiomyosarcoma AJCC v8
Metastatic Leiomyosarcoma
Recurrent Synovial Sarcoma
Recurrent Undifferentiated Pleomorphic Sarcoma
Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8
Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8
Metastatic Malignant Peripheral Nerve Sheath Tumor

Interventions: Drug: Pazopanib
Drug: Sapanisertib
Drug: Pazopanib Hydrochloride

First Posted Date: 2015-11-10

Last Posted Date: 2022-08-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 151

Registration Number: NCT02601209

Locations: 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸
Rocky Mountain Cancer Centers - Pueblo, Pueblo, Colorado, United States

and more 455 locations

Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Metastatic Lung Non-Small Cell Carcinoma
Stage IIIB Lung Non-Small Cell Cancer AJCC v7
Stage IV Lung Non-Small Cell Cancer AJCC v7
Stage III Lung Non-Small Cell Cancer AJCC v7
Recurrent Lung Non-Small Cell Carcinoma
Stage IIIA Lung Non-Small Cell Cancer AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Drug: Osimertinib
Other: Pharmacological Study
Drug: Sapanisertib

First Posted Date: 2015-07-21

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT02503722

Locations: 🇺🇸
Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇨🇦
BCCA-Vancouver Cancer Centre, Vancouver, British Columbia, Canada

and more 2 locations

Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia

Phase 2

Active, not recruiting

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
B Acute Lymphoblastic Leukemia
Refractory Adult Acute Lymphoblastic Leukemia
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative
Recurrent Adult Acute Lymphoblastic Leukemia
T Acute Lymphoblastic Leukemia

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sapanisertib

First Posted Date: 2015-06-29

Last Posted Date: 2024-11-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 16

Registration Number: NCT02484430

Locations: 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 11 locations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Breast Carcinoma
Cervical Carcinoma
Liver Carcinoma
Malignant Uterine Neoplasm
Recurrent Gastric Carcinoma
Recurrent Head and Neck Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Prostate Carcinoma
Recurrent Rectal Carcinoma

Interventions: Drug: Afatinib
Drug: Binimetinib
Drug: Adavosertib
Drug: Capivasertib
Drug: Afatinib Dimaleate
Procedure: Biospecimen Collection
Other: Cytology Specimen Collection Procedure
Drug: Dabrafenib
Drug: Fexagratinib
Drug: Dasatinib
Drug: Ipatasertib
Drug: Defactinib
Drug: Sapanisertib
Procedure: Biopsy
Drug: Crizotinib
Drug: Dabrafenib Mesylate
Drug: PI3K-beta Inhibitor GSK2636771
Drug: Defactinib Hydrochloride
Drug: Palbociclib
Biological: Nivolumab
Drug: Copanlisib
Drug: Taselisib
Drug: Ulixertinib
Drug: Copanlisib Hydrochloride
Biological: Trastuzumab Emtansine
Biological: Relatlimab
Procedure: Computed Tomography
Drug: Trametinib
Biological: Pertuzumab
Drug: Erdafitinib
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Drug: Larotrectinib
Drug: Larotrectinib Sulfate
Procedure: Echocardiography
Drug: Osimertinib
Biological: Trastuzumab
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Vismodegib
Drug: Sunitinib Malate
Procedure: Radionuclide Imaging

First Posted Date: 2015-06-08

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6452

Registration Number: NCT02465060

Locations: 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
Thomas Hospital, Fairhope, Alabama, United States
🇺🇸
Mobile Infirmary Medical Center, Mobile, Alabama, United States

and more 1416 locations

Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer

Phase 2

Completed

Conditions: Recurrent Lung Squamous Cell Carcinoma
Stage IV Lung Squamous Cell Carcinoma AJCC v7

Interventions: Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Drug: Sapanisertib

First Posted Date: 2015-04-16

Last Posted Date: 2022-04-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 34

Registration Number: NCT02417701

Locations: 🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 4 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy